Lendormin (Brotizolam)

Brotizolam binds to a specific site on the GABAA receptor complex, acting as a positive allosteric modulator. This enhances the natural inhibitory action of GABA, increasing chloride ion flow into neurons, which reduces neuronal excitability and produces a calming, hypnotic effect.

The exact dose of Lendormin is determined by the prescribing clinician based on the individual’s age, severity of insomnia, and overall health status. Physicians typically start with the lowest effective dose and adjust as needed, following local prescribing guidelines.

Safety data for brotizolam in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Lendormin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lendormin (brotizolam) belongs to the benzodiazepine class, offering rapid onset of sleep and a relatively short half‑life compared with some longer‑acting agents. Compared with non‑benzodiazepine hypnotics such as zolpidem, brotizolam may have a higher risk of dependence but can be useful for patients who need a potent, short‑acting sedative.

Lendormin tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct light, and ensure they are out of reach of children. Do not use the product after the expiry date printed on the packaging.

Lendormin is taken orally as a tablet, usually with a glass of water. It is typically prescribed to be taken shortly before bedtime, and patients are advised to avoid activities requiring full alertness, such as driving, after taking the medication.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, the potential for physical dependence and withdrawal symptoms, and rare but severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience difficulty breathing, severe rash, or swelling.

Lendormin is contraindicated in children, patients with severe hepatic impairment, those with a known hypersensitivity to brotizolam or other benzodiazepines, and individuals with a history of substance abuse or dependence. It should also be avoided in patients with acute narrow‑angle glaucoma.